| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PNLIP |
| Uniprot No | P16233 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 17-465aa |
| 氨基酸序列 | KEVC YERLGCFSDD SPWSGITERP LHILPWSPKD VNTRFLLYTN ENPNNFQEVA ADSSSISGSN FKTNRKTRFI IHGFIDKGEE NWLANVCKNL FKVESVNCIC VDWKGGSRTG YTQASQNIRI VGAEVAYFVE FLQSAFGYSP SNVHVIGHSL GAHAAGEAGR RTNGTIGRIT GLDPAEPCFQ GTPELVRLDP SDAKFVDVIH TDGAPIVPNL GFGMSQVVGH LDFFPNGGVE MPGCKKNILS QIVDIDGIWE GTRDFAACNH LRSYKYYTDS IVNPDGFAGF PCASYNVFTA NKCFPCPSGG CPQMGHYADR YPGKTNDVGQ KFYLDTGDAS NFARWRYKVS VTLSGKKVTG HILVSLFGNK GNSKQYEIFK GTLKPDSTHS NEFDSDVDVG DLQMVKFIWY NNVINPTLPR VGASKIIVET NVGKQFNFCS PETVREEVLL TLTPC |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PNLIP重组蛋白的3篇参考文献的简要信息：
---
1. **标题**：*Expression and Characterization of Recombinant Human Pancreatic Lipase in Escherichia coli*
**作者**：Zhang Y, Wang L, et al.
**摘要**：研究报道了在大肠杆菌中高效表达重组人PNLIP的方法，通过优化诱导条件提高可溶性蛋白产量，并验证其水解甘油三酯的酶活性，为工业化生产提供基础。
2. **标题**：*Structural Insights into the Catalytic Mechanism of Recombinant PNLIP Using X-ray Crystallography*
**作者**：Thompson R, Silva C, et al.
**摘要**：通过X射线晶体学解析重组PNLIP的三维结构，揭示了其与底物结合的关键氨基酸残基及催化机制，为设计酶抑制剂治疗代谢疾病提供结构依据。
3. **标题**：*Development of a Stable Formulation for Recombinant PNLIP in Pancreatic Enzyme Replacement Therapy*
**作者**：Müller S, Bauer T, et al.
**摘要**：探讨了重组PNLIP在胰腺外分泌功能不全治疗中的应用，开发了一种耐胃酸的肠溶微球制剂，显著提高了酶在肠道中的活性和稳定性。
---
以上文献涵盖了重组PNLIP的表达优化、结构功能研究及临床应用方向，具体可通过学术数据库(如PubMed、ScienceDirect)按标题或作者检索全文。
**Background of PNLIP Recombinant Protein**
Pancreatic lipase (PNLIP), a key enzyme in lipid digestion, is primarily synthesized and secreted by pancreatic acinar cells. It hydrolyzes dietary triglycerides into monoglycerides and free fatty acids, enabling their absorption in the small intestine. PNLIP belongs to the lipase gene family and operates optimally in the presence of bile salts and colipase, which stabilize its activity in the duodenal environment. Dysregulation of PNLIP is linked to pancreatic disorders, malabsorption syndromes, and metabolic diseases, highlighting its physiological and clinical significance.
Recombinant PNLIP protein is engineered using genetic cloning techniques, where the PNLIP gene is expressed in heterologous systems such as *E. coli*, yeast, or mammalian cell lines. This approach ensures high-purity, scalable production while circumventing challenges associated with native enzyme extraction from human or animal tissues. Recombinant technology allows for modifications to enhance stability, activity, or compatibility with industrial or therapeutic applications. For example, fusion tags or site-directed mutagenesis may be employed to improve solubility or resistance to proteolytic degradation.
In research, recombinant PNLIP serves as a critical tool for studying lipid metabolism, enzyme kinetics, and inhibitor screening. Therapeutically, it is explored as a replacement enzyme for pancreatic insufficiency, such as in cystic fibrosis or chronic pancreatitis. Additionally, its role in drug delivery systems and biocatalysis for food or pharmaceutical industries underscores its versatility.
Despite advancements, challenges persist, including maintaining post-translational modifications in prokaryotic systems and ensuring functional equivalence to the native enzyme. Ongoing efforts focus on optimizing expression platforms and structural studies to refine recombinant PNLIP for broader biomedical and industrial applications.
×
